FDA (CDER)
GUIDANCE FINAL
Psychedelic Drugs: Considerations for Clinical Investigations
Published: 7/14/2026Detected: 7/13/2026
Summary preview
Outlines FDA’s key considerations for designing, conducting, and monitoring clinical investigations involving psychedelic drugs, with an emphasis on patient safety, protocol rigor, and appropriate risk mitigation.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpsychiatry
neurology
cardiology
safety
clinical
#psychedelic drugs
#clinical investigations
#adverse event reporting
#risk mitigation
#protocol design
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026